Literature DB >> 34518633

Unusual lung tumors-from morphology to genetics.

Jennifer M Boland1.   

Abstract

Most pathologists are well versed in the diagnosis of lung cancer, given the common nature of the disease. Occasionally more unusual neoplasms are encountered in lung biopsies and resections, which may be difficult to distinguish from "run of the mill" lung cancer cases based on overlapping morphologic and immunophenotypic features. The accurate diagnosis of these rare entities is quite challenging and requires careful morphological examination paired with judicious use of ancillary immunohistochemical and genetic studies. Herein, the clinicopathological and genetic features of five unusual lung tumors will be reviewed, including thoracic SMARCA4-deficient undifferentiated tumor, NUT carcinoma, sclerosing pneumocytoma, primary pulmonary myxoid sarcoma/angiomatoid fibrous histiocytoma, and bronchiolar adenoma/ ciliated muconodular papillary tumor. Since recognition of these entities by pathologists is of increasing importance to guide prognosis and therapy, emphasis will be placed on practical tips to reach these rare diagnoses with confidence.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34518633     DOI: 10.1038/s41379-021-00914-7

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  60 in total

1.  SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.

Authors:  David L Kolin; Fei Dong; Michele Baltay; Neal Lindeman; Laura MacConaill; Marisa R Nucci; Christopher P Crum; Brooke E Howitt
Journal:  Mod Pathol       Date:  2018-04-26       Impact factor: 7.842

2.  Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.

Authors:  Martin Hasselblatt; Stefan Gesk; Florian Oyen; Sabrina Rossi; Elisabetta Viscardi; Felice Giangaspero; Caterina Giannini; Alexander R Judkins; Michael C Frühwald; Tobias Obser; Reinhard Schneppenheim; Reiner Siebert; Werner Paulus
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

3.  SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies.

Authors:  Abbas Agaimy; Deepali Jain; Nasir Uddin; Lisa M Rooper; Justin A Bishop
Journal:  Am J Surg Pathol       Date:  2020-05       Impact factor: 6.394

4.  SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg/CK7pos/HepPar-1pos immunophenotype.

Authors:  Abbas Agaimy; Florian Fuchs; Evgeny A Moskalev; Horia Sirbu; Arndt Hartmann; Florian Haller
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

5.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.

Authors:  Akihiko Yoshida; Eisuke Kobayashi; Takashi Kubo; Makoto Kodaira; Toru Motoi; Noriko Motoi; Kan Yonemori; Yuichiro Ohe; Shun-Ichi Watanabe; Akira Kawai; Takashi Kohno; Hiroshi Kishimoto; Hitoshi Ichikawa; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

6.  SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.

Authors:  Jennifer L Sauter; Rondell P Graham; Brandon T Larsen; Sarah M Jenkins; Anja C Roden; Jennifer M Boland
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

7.  SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.

Authors:  Raul Perret; Lara Chalabreysse; Sarah Watson; Isabelle Serre; Stephane Garcia; Fabien Forest; Violaine Yvorel; Daniel Pissaloux; Vincent Thomas de Montpreville; Julien Masliah-Planchon; Sylvie Lantuejoul; Marie Brevet; Jean-Yves Blay; Jean-Michel Coindre; Franck Tirode; Francois Le Loarer
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

8.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Authors:  Francois Le Loarer; Sarah Watson; Gaelle Pierron; Vincent Thomas de Montpreville; Stelly Ballet; Nelly Firmin; Aurelie Auguste; Daniel Pissaloux; Sandrine Boyault; Sandrine Paindavoine; Pierre Joseph Dechelotte; Benjamin Besse; Jean Michel Vignaud; Marie Brevet; Elie Fadel; Wilfrid Richer; Isabelle Treilleux; Julien Masliah-Planchon; Mojgan Devouassoux-Shisheboran; Gerard Zalcman; Yves Allory; Franck Bourdeaut; Francoise Thivolet-Bejui; Dominique Ranchere-Vince; Nicolas Girard; Sylvie Lantuejoul; Francoise Galateau-Sallé; Jean Michel Coindre; Alexandra Leary; Olivier Delattre; Jean Yves Blay; Franck Tirode
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

9.  SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.

Authors:  Abbas Agaimy; Ondrej Daum; Bruno Märkl; Ines Lichtmannegger; Michal Michal; Arndt Hartmann
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

10.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.

Authors:  Natasha Rekhtman; Joseph Montecalvo; Jason C Chang; Deepu Alex; Ryan N Ptashkin; Ni Ai; Jennifer L Sauter; Brie Kezlarian; Achim Jungbluth; Patrice Desmeules; Amanda Beras; Justin A Bishop; Andrew J Plodkowski; Mrinal M Gounder; Adam J Schoenfeld; Azadeh Namakydoust; Bob T Li; Charles M Rudin; Gregory J Riely; David R Jones; Marc Ladanyi; William D Travis
Journal:  J Thorac Oncol       Date:  2019-11-18       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.